AMS is a excellent company and the share price deserves to be high, but as indeed is shown on the graph above, the shares did go somewhat frothy, hence the pull back which may go further yet. I would not be surprised to see a gradual fall to 260p or thereabouts - when the PE-ratio will look less toppy. |
IMO selling has been caused due to this: |
very quiet here.
The share price has stabilised over the past week or so and given its track record/strong IPR and growing presence in the US i cant help think that a few of the bigger US pharma groups are not running the numbers on a bid for AMS.
At the peak share price a year ago of circa £3.60 and an exchange rate of 1.30 this was valued at $1bn. Now at £2.86 and an exchange rate of 1.2 it has a market cap of $750m and in the interim has acquired Sealantis which strengthens its presence in the US.
I have no knowledge of any bid and would expect a big premium but definitely an opportune time for an American "invader"?
The forecasts for 2019 are for small fall in EPS - partly due to Sealantis which is slightly dilutive and the slower first half - would be good if the interims suggest they can improve upon that. |
 Hi Dealit:
FDA approval for two new AMS wound care products--which testify to the company's continuing desire to innovate and grow revenues organically--was announced, as you point out, on July 30th. I agree that it is disappointing and somewhat puzzling that the share price did not turn sharply upwards at this very welcome development, though I wonder whether it may have taken a day or so for investors to catch up with the news. If you look at the trajectory of the share price from July 31st to today, it is easy to spot a clear, albeit modest, upward trend (delineated by higher highs and higher lows). Just where this upswing will end is a matter of guesswork in a market that is so badly depressed by global events that have most investors rattled.
In my view, AMS is a world class company, whose success in the future promises to be every bit as exciting as it has been over past years. It fits Jim Slater's celebrated Zulu principle perfectly. I still hold all of the shares I bought years ago (for an average in single digits) and, as long as the stellar performance is repeated, year in, year out, I cannot imagine wanting to sell them. A take over would obviously force my hand but I would strongly resist surrendering my holding at less than £5.00 a share. |
FDA approval for 2 AMS products today and the share price drops out of favour indeed. |
Sellers > £3 & buyers sub-£3. |
Wetdream, AMS are a solid Company and the announcement was not a profits warning. Historically the share price bounces for no reason other than MM`s trying to loosen shares IMHO. Have a read of the Chairmans statement;
"I am pleased to report that overall the Group continues to perform well and we are trading in line with the Board's expectations for the full year. Looking ahead, we are excited about the growth prospects for the business, the integration of Sealantis and the expected impact from new product launches. AMS is in a robust position and we are confident on delivering our stated growth strategy." |
Hi dealit,
Agreed. But c.200k sold earlier (11.45-13.50) in five-figure blocks.
Probably just me getting a bit p!ssed off with the co. And its updates! |
Just had a look, all I can see is a buy at £302 182,019 share bought. |
Seems like we have a big seller at £3. |
Let us hope no more positive announcements this week the last one sent the share price south by 4%,MMs playing games here trying to loosen stock IMHO. |
Probably won't be the only co. in the medical/pharmaceutical field to be blinsided by stocking/destocking due to Brexit. |
You are getting confused with liquiband and liquiband fix8 which is the device. Liquiband is the substance used in the device for hernia repair. Completely different. |
AMS have singled out Liquiband which was designed and is made for AMS by Surgical Innovations (SUN) as the cause of their problems.
So AMS have IMO kicked their supplier in the nuts … which is not very fair as Liquiband sales in the USA are only a couple of $ Million a year.
So I don't buy the rationale. |
Big drop on opening trading today. Trading statement says trading in line with the boards expectations who will know the figures, let us hope we can hold around £3 until result. Flip side is the cheaper they become will look more attractive to a predator IMHO. |
Good entry point at £3 |
Today's Trading Statement sound positive overall, but I wounder whether
Trump's "America First" attitude could have a negative impact on sales
of AMS's LiquiBand, as there are US competitors in that field. |
Half the shares are held by eight institutions, so not much of a free float.
Only takes one seller to push the share price down as the instis just seem to hold what they've got.
Who knows? Perhaps Woodford's got some he needs to get rid of! |
Perhaps a little step back to reality, the share price had become a little too frothy. |
I think this has been hit by the large number of cancelled operations in the NHS in the last quarter, See SUN |
AGM today 11am |
Price dropped to accommodate the 700k buy? |
Looks like the +ve news re the IDE announcement's sinking in. |
Good news. 👍 |
Liquiband fix8 USA approval progressing. Commenting on the announcement, Chris Meredith, CEO of AMS, said: "LiquiBand(R) Fix8(TM)has been growing sales strongly and receiving very positive feedback from surgeons in the European market and we are delighted that we can now start a study with our proprietary device that could benefit patients in the US market. Innovation is at the heart of AMS and this is just one example of our devices that helps patients, surgeons and healthcare payors. We look forward to reporting on further development with LiquiBand(R) Fix8(TM) as it grows sales and receives further approvals."Should also provide positive support for surgical innovations who manufacture the device for AMS . |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
